HALOPERIDOL DECANOATE

Post-LOE

haloperidol decanoate

Viatris (2)

ANDAINJECTIONINJECTABLE

Approved

Feb 2000

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

HALOPERIDOL DECANOATE (haloperidol decanoate) by Viatris (2) is clinical pharmacology haloperidol decanoate injection, 50 mg/ml and haloperidol decanoate injection, 100 mg/ml are the long-acting forms of haloperidol, an antipsychotic. Approved for schizophrenia. First approved in 2000.

Drug data last refreshed 20h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Haloperidol decanoate injection, 50 mg/mL and haloperidol decanoate injection, 100 mg/mL are the long-acting forms of haloperidol, an antipsychotic. The mechanism of action of haloperidol for the treatment of schizophrenia is unclear. However, its efficacy could be mediated…

Indications (1)

schizophrenia

Worked on HALOPERIDOL DECANOATE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.